GTS Securities’s Edwards Lifesciences EW Stock Holding History

GTS Securities’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$388K	Sell	4,847 -616	-11%	-$50.8K	0.01%	911
2025 Q4	$466K	Buy	+5,463	New	+$448K	0.02%	827
2025 Q2	–	Sell	-4,678	Closed	-$339K	–	1336
2025 Q1	$339K	Sell	4,678 -65	-1%	-$4.65K	0.01%	884
2024 Q4	$351K	Sell	4,743 -24,203	-84%	-$1.69M	0.02%	791
2024 Q3	$1.91M	Buy	28,946 +22,848	+375%	+$1.66M	﹤0.01%	1598
2024 Q2	$563K	Buy	+6,098	New	+$540K	﹤0.01%	2595
2024 Q1	–	Sell	-28,404	Closed	-$2.39M	–	4013
2023 Q4	$2.17M	Buy	28,404 +25,248	+800%	+$1.76M	﹤0.01%	1596
2023 Q3	$219K	Buy	+3,156	New	+$254K	﹤0.01%	3341

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GTS Securities's EW Position: Q1 2026 in Review

GTS Securities reduced its Edwards Lifesciences (EW) stake by 11% in Q1 2026, selling an estimated $50.8K and leaving 4,847 shares worth $388K. The position accounts for 0.01% of the portfolio, ranked #911.

GTS Securities first reported a position in EW in Q3 2023 and has held it in 8 quarters since. The position peaked at $2.17M in Q4 2023. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

GTS Securities held 4,847 shares of Edwards Lifesciences worth $388K as of Q1 2026.
GTS Securities sold 616 Edwards Lifesciences shares in Q1 2026, an estimated $50.8K.
Edwards Lifesciences made up 0.01% of GTS Securities's portfolio in Q1 2026, its #911 holding.
GTS Securities first reported a position in Edwards Lifesciences in Q3 2023 and has held it in 8 quarters since.
GTS Securities's Edwards Lifesciences position peaked at $2.17M in Q4 2023.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.